The impact of MRD in apheresis product in patients with myeloma undergoing autoSCT

MRD negativity in myeloma patients undergoing maintenance therapyПодробнее

Using MRD to drive maintenance therapy decisions in patients with myeloma after autoSCTПодробнее

The impact of sustained undetectable MRD on survival in patients with myeloma treated with ide-celПодробнее

MRD as a predictor of risk in myelomaПодробнее

Impact of sustained MRD negativity and CR after ide-cel in patients with multiple myelomaПодробнее

Where does MRD belong as a tool in myeloma?Подробнее

Using MRD after autoSCT as a benchmark for consolidation strategies in myelomaПодробнее

Impact of pre-transplant MRD status on disease outcomes in patients with multiple myelomaПодробнее

Should we change our clinical practice for Multiple Myeloma based on MRD?Подробнее

What is minimal residual disease (MRD) and how can it help speed up new myeloma drug approvals?Подробнее

Medical Animation: Multiple Myeloma Minimal Residual Disease (MRD)Подробнее

COMMANDER trial: iberdomide combinations to eliminate MRD after induction and autoSCT in myelomaПодробнее

What does it mean when a myeloma patient is MRD negative?Подробнее

Prognostic value of early bone marrow MRD status in CAR-T therapy for multiple myelomaПодробнее

How does minimal residual disease (MRD) testing affect treatment decisions?Подробнее

Using MRD to understand the response to autoSCT in patients with multiple myelomaПодробнее

Understanding MRD and What It Means for Myeloma PatientsПодробнее

Is MRD testing routinely recommended for myeloma patients?Подробнее

The value of MRD in transplant-ineligible patients with multiple myelomaПодробнее